Major investment boost for South Roscommon pharma company
Novo Nordisk employs 400 at its Monkland plant.
Danish drugmaker, Novo Nordisk, is set to expand its plant in Monksland, according to its chief executive.
A major investment plan will see the company manufacture the Wegovy weight loss pill at the South Roscommon facility for markets outside the United States.
Novo already makes the popular obesity pill for the US market in the US.
In September last year, Novo announced plans to cut 75 of the 400 jobs at the Monksland plant as part of a 9,000 reduction in headcount worldwide.
In a recent interview with Bloomberg media about the expansion plans in South Roscommon, Mr Doustar remarked: “If we were about to throw in the towel, we would not be investing in factories in Ireland.”
Novo Nordisk purchased the former Elan Drug Technologies plant from Irish-headquartered pharma group Alkermes in 2024 in a deal worth €85m at the time.
